Hansoh Pharmaceutical's (HKG:3692) biologics license application for HS-20093 for injection was accepted by China's National Medical Products Administration.
The acceptance is for the treatment of osteosarcoma patients 12 years of age and above who have failed at least two prior lines of therapy, a Thursday bourse filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.